Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
News|Articles|January 6, 2025
Presenting Our January Theme: Cognition
Author(s)Leah Kuntz
Listen
0:00 / 0:00
Key Takeaways
- Addressing cognitive impairment in schizophrenia is essential for managing negative symptoms effectively.
- Innovative treatment strategies are necessary to combat cognitive deficits in psychiatric practice.
Do you want to be featured in a future Special Report? Check out our January theme!
Advertisement
Psychiatric Times is featuring monthly themes that speak to various aspects of psychiatry and issues relevant to psychiatric clinicians. Our January theme takes a look at a critical issue: Cognition. How do you combat negative symptoms of schizophrenia like cognitive impairment? What treatment strategies do you utilize?
If you have something you want to share, whether that's an article, case study example, or CME article, let us know! Write to us now at
Advertisement
Related to this article
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
5